Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Asahi Kasei Life Science Corporation currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Despite having multiple actions, they are all concentrated within 1 distinct art unit, indicating a very specific technical focus for the company's current life science research. This concentration allows for a consistent application of technical standards across the pending matters. For a practitioner, this means that the prosecution strategy can be highly specialized to the rules and trends of this single art unit.
The portfolio involves 2 distinct examiners, with ALLEN, MICHAEL D identified as the busiest examiner. This examiner is responsible for 1 busiest examiner pending office action. Since the 2 pending office actions are split between 2 distinct examiners but remain in the same art unit, the company must manage different individual examination styles while adhering to the same art unit guidelines. This suggests a strategy of pursuing related innovations that fall under the same technical classification. This structure allows the legal team to focus on the specific technical requirements and precedents of a single division within the patent office, even while coordinating with multiple examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17802030 | METHOD FOR EVALUATING VIRAL CLEARANCE CAPABILITY | KINSEY WHITE, NICOLE ERIN | 22d |
| 18283596 | VIRAL CLEARANCE TEST METHOD | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17802030 | METHOD FOR EVALUATING VIRAL CLEARANCE CAPABILITY | KINSEY WHITE, NICOLE ERIN | 22d |
| 18283596 | VIRAL CLEARANCE TEST METHOD | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283596 | VIRAL CLEARANCE TEST METHOD | ALLEN, MICHAEL D | 1671 | §103§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 17802030 | METHOD FOR EVALUATING VIRAL CLEARANCE CAPABILITY | KINSEY WHITE, NICOLE ERIN | 1671 | §102§112 | Non-Final OA | 22d | Pending | Aug 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAsahi Kasei Life Science Corporation has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Michael D Allen has the most, with 1 of Asahi Kasei Life Science Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
